Similar articles

• NIH faces marching orders on orphan drug shortage.

  Dolgin E. Dolgin E. Nat Med. 2011 May;17(5):522. doi: 10.1038/nm0511-522b. Nat Med. 2011. PMID: 21546953 No abstract available.
• New products highlight ambiguity of orphan drug law.

  Reid B. Reid B. Nat Biotechnol. 2003 Jan;21(1):6-7. doi: 10.1038/nbt0103-6b. Nat Biotechnol. 2003. PMID: 12511896 No abstract available.
• [Enzyme therapy in Fabry disease: when scarcity of one enzyme illustrates the vulnerability of biotech].

  Lidove O, Choukroun G, Bekri S, Viot G, Tsimaratos M, Joly D. Lidove O, et al. Presse Med. 2010 May;39(5):527-9. doi: 10.1016/j.lpm.2010.01.002. Epub 2010 Mar 2. Presse Med. 2010. PMID: 20194001 French. No abstract available.
• Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT).

  Linthorst GE, Germain DP, Hollak CE, Hughes D, Rolfs A, Wanner C, Mehta A; European Medicines Agency. Linthorst GE, et al. Mol Genet Metab. 2011 Jan;102(1):99-102. doi: 10.1016/j.ymgme.2010.11.155. Epub 2010 Nov 30. Mol Genet Metab. 2011. PMID: 21123099
• Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act.

  Arno PS, Bonuck K, Davis M. Arno PS, et al. Milbank Q. 1995;73(2):231-52. Milbank Q. 1995. PMID: 7776947 Review.